Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home Companies4DMEDICAL Ltd

4DMEDICAL Ltd

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
2.28 AUD -0.13 ( 5.39%)
Last update at 2026-11-06T06:17:00Z
VOLUME
6876708
Market Cap
1451.64M

Momentum Score

…

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. 4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.21
Low
2.39
High
52 Week Price Range
1.40
Low
7.55
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

4DMedical develops XV Technology, a software platform that generates lung ventilation and perfusion maps from standard X‑ray images to aid diagnosis and monitoring. Growth may be supported by rising respiratory disease prevalence, wider hospital adoption and recurring software and service revenue. The company appears positioned to offer a lower-cost, non-invasive alternative to CT and nuclear imaging, which could appeal to investors seeking software-led medical imaging exposure.

Key risks include regulatory and reimbursement uncertainty, competition from established imaging modalities, limited commercial traction and the need for additional capital.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.41
Dividend Yield
-
Revenue TTM
7.06M
Revenue Per Share
0.01
Gross Profit TTM
6.62M
Debt / Equity
0.02
ROE
-174.43%
Net Debt
-274.74M
ROCE
-16.14%
Diluted EPS TTM
-0.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Income before tax -210.23M -35.36M -35.36M -35.93M -40.40M
Net income -204.44M -30.07M -30.07M -35.98M -35.98M
Selling general administrative - 34.80M 34.80M 28.75M -
Selling and marketing expenses - - - 1.41M -
Gross profit -38.08M 5.39M 5.39M 3.52M -28.38M
Reconciled depreciation - 5.33M 5.33M 4.06M -
Ebit -57.46M -48.16M -48.16M -35.92M -48.22M
Ebitda -52.00M -45.82M -45.82M -31.86M -44.16M
Depreciation and amortization 5.46M 2.34M 2.34M 4.06M 4.06M
Operating income -57.46M -47.50M -47.50M -27.97M -48.22M
Other operating expenses 64.52M 35.07M 35.07M 31.72M 51.98M
Interest expense 2.73M 0.26M 0.26M 0.26M 0.26M
Tax provision - -0.09M -0.09M 0.05M -
Interest income - 0.34M 0.34M 1.24M -
Net interest income - 0.08M 0.08M 0.97M -
Income tax expense -5.80M -5.29M -5.29M 0.05M -4.42M
Total revenue 7.06M 5.85M 5.85M 3.75M 3.75M
Total operating expenses 19.38M 34.61M 34.61M 31.48M 19.84M
Cost of revenue 45.14M 0.46M 0.46M 0.24M 32.13M
Total other income expense net -152.78M 12.14M 12.14M -7.96M 7.83M
Net income from continuing ops - -30.07M -30.07M -35.98M -
Net income applicable to common shares - -30.07M -30.07M -35.98M -
Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Total assets 365.34M 94.81M 94.81M 120.02M 120.02M
Intangible assets 25.74M 23.86M 27.53M 29.46M -
Other current assets 2.32M 7.85M 7.85M 6.19M 1.56M
Total liab 195.17M 30.58M 30.58M 49.09M 49.09M
Total stockholder equity 170.16M 64.24M 64.24M 70.93M 70.93M
Other current liab 5.17M 12.94M 11.25M 17.58M 14.84M
Common stock 544.38M 239.97M - 218.43M 218.43M
Capital stock - 239.97M 239.97M 218.43M -
Retained earnings -386.54M -182.11M -182.11M -152.04M -152.04M
Good will 42.71M 42.71M 42.71M 42.71M -
Cash 277.95M 6.88M 6.88M 30.61M 30.61M
Total current liabilities 9.42M 19.25M 19.25M 21.89M 21.89M
Current deferred revenue 0.80M - - 1.01M 1.01M
Net debt -274.74M -2.57M - -25.49M -25.49M
Short term debt 1.03M 2.18M - 1.89M 0.94M
Short long term debt total 3.22M 4.31M - 5.12M 5.12M
Other stockholder equity - -0.40M - -0.36M -
Property plant equipment - 7.47M - 8.75M -
Total current assets 289.95M 17.06M 17.06M 39.05M 39.05M
Net receivables 9.46M 1.41M 1.19M 1.26M 5.89M
Inventory 0.22M 0.92M 0.92M 0.99M 0.99M
Accounts payable 2.42M 4.13M 1.87M 2.10M 5.10M
Accumulated other comprehensive income 12.33M 6.37M - 4.53M 4.53M
Non currrent assets other - 3.66M - 0.04M 72.17M
Non current assets total 75.39M 77.75M 77.75M 80.96M 80.96M
Capital lease obligations - 4.31M 4.31M 5.12M -
Long term debt total - 3.22M - 4.18M -
Breakdown 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-12-31 2024-06-30 2023-12-31
Investments - -1.62M -1.62M -40.04M -
Total cashflows from investing activities -2.43M -1.62M -1.62M -40.04M -
Total cash from financing activities 304.78M 12.37M 12.37M 31.94M 31.94M
Net income -204.44M -30.07M -30.07M -35.98M -35.98M
Change in cash 271.08M -23.73M -23.73M -38.97M -38.97M
Begin period cash flow 6.88M 30.61M 30.61M 69.58M 69.58M
End period cash flow 277.95M 6.88M 6.88M 30.61M 30.61M
Total cash from operating activities -31.27M -34.48M -34.48M -30.87M -30.87M
Issuance of capital stock - 14.70M 14.70M 35.00M -
Depreciation 5.46M 5.33M 5.33M 4.06M 4.06M
Other cashflows from investing activities -1.16M -1.24M -1.24M -1.02M -
Change to inventory - -0.07M -0.07M 0.33M -
Change to account receivables - 3.16M 3.16M -0.30M -
Sale purchase of stock - -1.36M -1.36M - -
Other cashflows from financing activities -1.09M - - -2.05M -40.04M
Capital expenditures 0.95M 0.09M 0.09M 0.30M 0.30M
Change in working capital - -12.20M -12.20M 0.70M -
Stock based compensation - 2.73M 2.73M 2.18M -
Other non cash items 167.70M -0.27M -0.27M 0.34M 9.18M
Free cash flow -32.22M -34.56M -34.56M -31.17M -31.17M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
4DX
4DMEDICAL Ltd		 -0.13
5.39%		 2.28 - - 205.57 8.53 170.03 -7.29
PME
Pro Medicus Ltd		 -3.10
1.49%		 205.13 81.98 106.38 83.13 43.70 74.38 95.34
CGS
Cogstate Ltd		 -0.09
2.66%		 3.29 33.80 27.86 9.59 6.95 6.35 19.27
AYA
ARTRYA Ltd		 -
-%		 3.50 - - 20505.14 7.00 16927.51 0.33
EIQ
Echoiq Ltd		 -0.02
3.85%		 0.50 - - 4187.55 32.81 4052.59 -8.27

Profile*

4DMEDICAL Ltd

4DMedical Limited operates as a medical technology company in the United States and Australia. The company engages in medical research technology and development of a non invasive respiratory imaging solution. It offers CT:VQ, non-contrast post processing technology; CAC, a non-contrast cardiothoracic risk assessment sotware; CT LVAS, a regional lung function imaging software; IQ-UIP, a state-of-the-art software; LDAf, Patented Parametric Response Mapping (PRM) technology; LDAi, an automated detection of potential emphysema software; LTA provides visualization and quantification of the lung textures; PHA Analysis, a cutting-edge, fully-automated imaging solution; XV LVAS, a lung airflow imaging software; and XV Scanner, a lung function scanner. The company has partnership with AstraZeneca to launch and expand a lung health screening program; and a contractual engagement with GlaxoSmithKline to provide its proprietary quantitative lung imaging analytics in support of pulmonary drug development and clinical research. 4DMedical Limited was incorporated in 2012 and is based in Carlton, Australia.

Melbourne Connect, Carlton, VIC, Australia, 3053

61 3 9545 5940

https://4dmedical.com

181

Name Title Year Born
Dr. Andreas Fouras M.A.I.C.D., Ph.D. Founder, MD, CTO, CEO & Exec. Director NA
Mr. John Andrew Livingston BAppSci, GradCertBus, GradDipHSc Exec. Director NA
Mr. Simon Glover Chief Financial Officer NA
Mr. Craige Pendleton-Browne B.Sc., M.B.A. Chief Information Officer NA
Beth Plunkett Company Legal Counsel NA
Mr. Clint Rodgers VP of Marketing & Communications NA
Ms. Rachael Tenkaten Chief of Staff NA
Mr. Paul Cooke B.A. Sr. VP of Strategy & Bus. Devel. NA
Dr. Aidan Jamison B.E., Ph.D. Sr. VP of Engineering NA
Dr. Michael Curtis Ph.D. Chief Software Architect NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…